Format

Send to

Choose Destination
Rambam Maimonides Med J. 2014 Oct 29;5(4):e0024. doi: 10.5041/RMMJ.10158. eCollection 2014 Oct.

Dendritic cell cancer vaccines: from the bench to the bedside.

Author information

1
Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel; ; Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel.
2
Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel;
3
Hematological Malignancies and Bone Marrow Transplantation, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

Abstract

The recognition that the development of cancer is associated with acquired immunodeficiency, mostly against cancer cells themselves, and understanding pathways inducing this immunosuppression, has led to a tremendous development of new immunological approaches, both vaccines and drugs, which overcome this inhibition. Both "passive" (e.g. strategies relying on the administration of specific T cells) and "active" vaccines (e.g. peptide-directed or whole-cell vaccines) have become attractive immunological approaches, inducing cell death by targeting tumor-associated antigens. Whereas peptide-targeted vaccines are usually directed against a single antigen, whole-cell vaccines (e.g. dendritic cell vaccines) are aimed to induce robust responsiveness by targeting several tumor-related antigens simultaneously. The combination of vaccines with new immuno-stimulating agents which target "immunosuppressive checkpoints" (anti-CTLA-4, PD-1, etc.) is likely to improve and maintain immune response induced by vaccination.

KEYWORDS:

Cancer vaccines; dendritic cells; hematological malignancies; immunotherapy

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center